Biovu Launched To Provide Pivotal 'Go/No Go' Data In Growing Targeted Therapy Market

Nottingham, UK - 20 August 2002 - A new company has been launched to offer patient-based, 'proof-of-concept' medical imaging studies on a commercial basis for the first time to the growing number of pharmaceutical and biotechnology companies developing targeted therapy treatments.

Nottingham, UK-based biovu will utilise state-of-the-art imaging technology and expertise to assess the effectiveness of new products. Biovu has a particular therapeutic focus on the areas of oncology, respiratory disease and gastroenterology and is establishing a network of consultant physicians to recruit patients for studies. To compliment its imaging expertise, biovu has world class capability in radiolabelling a wide variety of formulations for use in its complex clinical trials.

Target-specific therapies include monoclonal antibodies or so-called 'magic bullets' and potentially provide better therapeutic treatments than conventional drugs. In cancer patients, for example, monoclonal antibodies or other similar therapeutic agents could be used to provide targeted chemotherapy, enhancing treatment and minimising side effects.

Biovu, a subsidiary of Pharmaceutical Profiles, will provide vital information on the viability of new targeted therapies in small numbers of patients during early clinical development to enhance the decision-making process. These 'proof-of-concept' studies could help save millions of dollars in development costs and speed up the development of novel, potentially life-saving therapeutics.

Figures from ING Barings suggest the market for monoclonal antibodies alone will grow dramatically in the future. At the moment there are only a handful of marketed monoclonal antibodies, however, Barings suggest around 80 products will be on the market by 2010. Currently, there are around 130 monoclonal antibody-based products in development and the global market could be worth as much as $15 billion by 2010. Some 53% of monoclonals in development are for cancer treatment, 25% for autoimmune diseases, 6% for infectious diseases, 6% for organ rejection prevention and around 4% for cardio vascular diseases.

"The real benefit to the industry of studies undertaken by biovu is the use of small numbers of patients in 'proof-of-concept' studies where we can truly assess the performance of new therapeutics before embarking on costly and time-consuming multi-centre studies", explained Dr Carole Kenyon, Chief Operating Officer. "The information provided by biovu on the delivery, biodistribution, targeting properties, safety and clearance of novel drugs will ensure that fewer unsuitable products are taken forward into Phase IIb development and beyond, only to subsequently fail".

She continued, "Launching a new company is never easy, but we believe that biovu is well positioned to streamline the decision process making a significant contribution towards helping bring new generations of therapies to market more quickly and efficiently."

biovu has already recruited a business development team to promote its groundbreaking services and is currently recruiting additional project management and operational staff.

ends

For further information, please contact:

Richard Gee    +44 115 950 8399    enquiries@gbcspr.com
Paul Clewlow    +44 115 974 9000    paul.clewlow@pharmprofiles.co.uk

Or     www.pharmprofiles.co.uk


THIS RELEASE HAS BEEN DISTRIBUTED BY WEBITPR (www.webitpr.com)

Disclaimer:

Whilst WebitPR.com Limited endeavour to ensure the accuracy of the information contained in this Release, WebitPR.com Limited cannot accept any liability for:-

·    the inaccuracy or otherwise of any information contained in this Release; or
·    any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release.; or
·    any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.

In the event that any information contained in this Release is inaccurate or misleading then please contact WebitPR.com at the above e-mail address.


This article is courtesy of http://www.medic-care-aid.com
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice, the author
name and URLs remain intact and clickable.

Submit Your Article